GlassScriptPhysician profile
Richard Schumacher
NPI 1275692295
$7,701.95
in general payments reported to CMS, 2019-2025
33 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $647 · 2021: $933 · 2022: $1,092 · 2023: $1,385 · 2024: $1,425 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,975 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,975.08 |
| Education | $187.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $789.23 | 2021-2025 | |
| Amgen INC. | $777.83 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $726.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $637.19 | 2019-2024 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $627.33 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $571.25 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $396.73 | 2019-2023 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $379.26 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $357.19 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $347.80 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $294.02 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $228.64 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $193.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.44 | 2020-2025 | Gattex |
| Otsuka America Pharmaceutical, INC. | $171.65 | 2019-2025 | Jynarque, Voyxact |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $149.52 | 2019-2025 | Velphoro |
| Daiichi Sankyo INC. | $123.89 | 2019-2021 | |
| Ardelyx, INC. | $114.86 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $112.94 | 2020-2023 | Benlysta |
| Baxter Healthcare | $109.67 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.57 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $41.41 | 2021-2023 | Amvuttra |
| Abbvie INC. | $39.68 | 2021-2022 | |
| Shire North American Group INC | $37.04 | 2019 | |
| Novo Nordisk INC | $34.97 | 2024-2025 | Ozempic, Rivfloza |
| Genzyme Corporation | $32.68 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $29.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.85 | 2023 | Ultomiris |
| Potrero Medical, INC. | $18.60 | 2022 | |
| Scpharmaceuticals INC. | $16.62 | 2025 | |
| Pfizer INC. | $15.67 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.59 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Schumacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.